Skip to content

Protagonist Therapeutics, Inc

PTGX Nasdaq SEC CIK 1377121

Follow Protagonist Therapeutics Weekly email: filings, results, news

News

10 stories filed under Protagonist Therapeutics, grouped into ongoing threads

FDA approval

Thread · 4 stories

MIMRYLO Approval Triggered $275M Payments for Protagonist (PTGX). Are Royalties the Better Commercial Model?

Markets 20 d ago

Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of Mimrylo for Erythrocytosis in Polycythemia Vera - Slideshow

Markets 24 d ago

Protagonist Therapeutics receives FDA approval for polycythemia vera drug

Markets 26 d ago

Protagonist Therapeutics: "Strong Buy" ICOTYDE FDA Approval And PN-881 Advancement

Markets 43 d ago also on PN

More coverage

Protagonist Therapeutics authorizes $300 million buyback plan

Markets 16 d ago

Protagonist (PTGX) Swings To A Profit As Two Drugs Near Blockbuster Status

Markets 18 d ago

Protagonist Therapeutics stock rating maintained at Buy by Clear Street

Markets 24 d ago 3 sources

Jefferies reiterates Protagonist Therapeutics stock rating on Mimrylo label strength

Markets 24 d ago

Protagonist Therapeutics stock hits all-time high at 155.01 USD

Markets 41 d ago

Protagonist Therapeutics CEO Dinesh Patel sells $14.9m in stock

Markets 42 d ago 2 sources

Next results

NOV4

Q2 2026 results

Wednesday · estimated from the filing cadence

Profile

Headquarters: NEWARK, CA, United States
Sector: Healthcare
Industry: Pharmaceutical Preparations

Peers

Where this page comes from

Profile · SEC EDGAR

Next results · estimated from the filing cadence (SEC EDGAR)

News · 10 stories clustered from the RSS aggregator